**Core Concept**
Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor, primarily used in the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). It works by inhibiting several pathways involved in tumor growth and angiogenesis, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and others.

**Why the Correct Answer is Right**
Sunitinib inhibits VEGFR-1, VEGFR-2, and VEGFR-3, which are key receptors involved in angiogenesis. This leads to decreased tumor blood supply, reduced tumor growth, and eventually, tumor regression. Additionally, sunitinib's inhibition of PDGFR-β helps to reduce tumor cell proliferation and survival.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because sunitinib is not primarily used as a treatment for breast cancer. While it may have some efficacy in certain types of breast cancer, it is not a standard treatment for this condition.
* **Option B:** This option is incorrect because sunitinib is not a chemotherapy agent. It is a targeted therapy, which works by inhibiting specific molecular pathways involved in tumor growth.
* **Option C:** This option is incorrect because sunitinib is not a monoclonal antibody. It is a small molecule inhibitor that binds to and inhibits specific tyrosine kinases.

**Clinical Pearl / High-Yield Fact**
Sunitinib's mechanism of action is primarily through the inhibition of angiogenesis, making it a valuable treatment option for tumors with high vascular endothelial growth factor (VEGF) expression. This is a key clinical correlation to remember when considering targeted therapies for RCC and GIST.

**Correct Answer: A. Sunitinib is not primarily used as a treatment for breast cancer.**